Latest Sunitinib Stories
A new blood test revealed more of the gene mutations that sustain certain digestive-tract tumors than did a DNA analysis of a traditional tumor biopsy.
Markers such as CA9, CD31, CD34 and VEGFR1/2 in the primary tumors might serve as predictors of a good response to a sunitinib treatment in patients with metastatic clear cell renal cell carcinoma (ccRCC).
A new targeted drug demonstrated its ability to control metastatic gastrointestinal stromal tumor, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies.
- Of or relating to good digestion.